DDInter1055 DDInter1484
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Plicamycin
Levofloxacin {u} (Compound) causes {v} (Side Effect) Gastritis
Gastritis {u} (Side Effect) is caused by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Plicamycin
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin
Levofloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Plicamycin
Levofloxacin (Compound) causes Gastritis (Side Effect) and Gastritis (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Plicamycin